Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Reig Jofre — FY2022 Earnings Presentation
26 slides from Laboratorio Reig Jofre's earnings presentation, 2023
Slide 1: Results 2022
RESULTS 2022 PHARMA INDUSTRY
Slide 2: Disclaimer
DISCLAIMER DECLARACIÓN Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail This presentation does not contain any confidential material and may include publicly Reig Jofre is under no obligation to publicly disclose the results of rev
Slide 3: Table of Contents
TABLE OF CONTENTS 01 REIG JOFRE TODAY 02 INCOME STATEMENT & BALANCE SHEET 03 PERFORMANCE OF THE RJF SHARE
Slide 4: Reig Jofre Today
REIG JOFRE TODAY 01 Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail
Slide 5: Reig Jofre Today: key figures 2022
A PHARMACEUTICAL COMPANY FOCUSED ON THE RESEARCH, DEVELOPMENT, REIG JOFRE TODAY MANUFACTURE AND MARKETING OF PHARMACEUTICALS MEDICINES AND FOOD SUPPLEMENTS 3 GENERATIONS YEARS OF TEAM LISTING CODE AT THE FOREFRONT OF THE BUSINESS HISTORY 1929 Ramon Reig Jofre Founder 1970 Joan M. Biosca Son-in-law o
Slide 6: Sales 2022 by business unit
SALES 2022 BUSINESS UNITS €271million +15% PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES PHARMACARE HEALTHCARE Antibiotics Osteoarticular OTC Injectables / Lyophilisates Dermatology Energy Stress and sleep Weight control Beauty €125.0 €80.4 €65.7 46 30 24 million million million % % % +16% +20% +7%
Slide 7: Pharmaceutical Technologies: CDMO manufacturing
PHARMACEUTICAL CDMO Product developed by manufacturing REIG JOFRE TECHNOLOGIES 125 M€ 20% 80% +20% 46 % CDMO OWN SALES LICENSING Antibiotics Injectables & MANUFACTURING NETWORK DISTRIBUTION 44% lyofilizates AGREEMENTS 50% 24M€ 35M€ 61M€ Other technologies 6% Toledo Barcelona Presence in 6 markets
Slide 8: Specialty Pharmacare
SPECIALTY CDMO Product developed by manufacturing REIG JOFRE PHARMACARE 80 M€ 10% 90% 30 % +7% FABRICACION RED COMERCIAL ACUERDOS CMO PROPIA LICENCIA Osteoarticular Dermatology DISTRIBUCION 60% 29% 8M€ 67M€ 5M€ Other Specialties 11% Barcelona Malmö ► New Dermatology Launches: DEXULAC, REGENAIL ► Sal
Slide 9: Consumer Healthcare
CONSUMER HEALTHCARE 66 M€ 24 % +16% Rest of Rest of ► REIG JOFRE #1 in otics in Spanish SPAIN EUROPE WORLD Weight control 19% pharmacies (Oto range, new brand 16M€ 47M€ 3M€ Energy image) 26% 25% 72% 3% Beauty ► FORTÉ PHARMA #1 in para-pharmacies 10% in France Health Respiratory/ ENT ► FORTÉ PHARMA b
Slide 10: International Performance
INTERNATIONAL PERFORMANCE Rest of Rest of SPAIN EUROPE WORLD TOTAL PRESENCE SALES 2022 44% 47% 9% +70 €271 €118.6million €127.2 million €25.4 million COUNTRIES million +12% +25% -13% DIRECT SALE 8 COUNTRIES €166 million Spain European 4 44% Union euros Group Companies, Own Sales Network 41% SPAIN -
Slide 11: Team: 1,213 people
TEAM 1.213 PEOPLE QUALIFIED EMPLOYMENT 59 % GENDER 22 NATIONALITIES CULTURAL 38 % HIGHER UNIVERSITY DEGREES 94 % JOB FULL TIME EMPLOYMENT EQUALITY DIVERSITY EDUCATION STABILITY France 125 7 Portugal Sweden 104 27 Poland Spain 941 9 Benelux Manufacturing 760 284 Sales & 63% Marketing 23% 101 R&D 8% T
Slide 12: Income Statement & Balance Sheet
INCOME STATEMENT & BALANCE SHEET 02 Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail
Slide 13: Income statement: EBITDA and sales
2021 2022 var thousands € Turnover 236.231 271.150 15% Cost of Materials -91.487 -113.094 Gross margin 144.744 158.056 9% Work carried out for fixed assets 3.640 3.063 Other operating income 528 480 Personnel expenses -64.185 -70.473 10% Other operating expenses -57.405 -60.690 6% million € EBITDA 2
Slide 14: Investment and balance sheet
INVESTMENT CAPEX INDUSTRIAL 2022 ASSET LIABILITY without IFRS 16 13,4 million € 10,3M R&D ACTIVATION 209M 195M 3,1M Amortisation Concepts AMORTISATION 8,6 17,4 EQUITY 2022 6,0 FIXED ASSETS 2,8 7M million € NON-FINANCIAL LIABILITIES 55M 62M CAPEX Industrial Productos, Marcas I+D NET WORKING CAPITAL F
Slide 15: Debt and leverage
LEASE DEBT APPLICATION IFRS 16 11,0 million € GROSS FINANCIAL DEBT DEBT WITH 57,8 million € 68,8 millIon € ASSET LIABILITY LENDING INSTITUTIONS 209M 195M Finace Lease 11% Loans 66% 80% Fixed Rste Public Loans 13% Working Capital Facilites 10% EQUITY FIXED ASSETS NON-FINANCIAL LIABILITIES 7M NET FINA
Slide 16: Reig Jofre 2013 - 2022
REIG JOFRE 2013 - 2022 R&D EXPENSE AND INVESTMENT Sales performance million euros 13,9 million euros 271 11,8 11,5 230 236 10,6 10,9 9,9 200 9,1 180 168 157 161 155 6,6 6,6 6,5 118 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 GASTO I+D EBITDA pe
Slide 17: Strategic Plan 2022 - 2027
Strategic Plan REIG JOFRE 2022 - 2027 PRODUCT/ INDUSTRIAL BUSINESS R&D TECHNOLOGY INVESTMENTS INVESTMENTS INVESTMENTS 2014 2018 2017-2018 Extension Toledo antibiotics plant Forté Pharma Lab. 2015 + 2021 JV Syna Therapeutics 2027 Derma UK 2020 2018-2021 Creation RJ UK Development >10 New injectables
Slide 18: Reig Jofre during the COVID pandemic 2020-22
REIG JOFRE during the COVID pandemic 2020-22 2020 REIG JOFRE is committed to ensuring the RJF holds 50specialties on the list of 350 supply of essential medicines to hospital ICUs essential medicines identified to ensure public during the COVID pandemic health 2021 Active role in the fight against t
Slide 19: Strategic autonomy of the EU
ff ES itizen in health Strategic autonomy of the
Slide 20: New injectable and lyophilizate plant, Barcelona
NEW RJ INJECTABLE & LYOPHILIZATE PLANT ● BARCELONA STATE-OF-THE-ART INJECTABLE PLANT INVESTMENT NEW PEOPLE HIRING ANNUAL CAPACITY HIGH CAPACITY & TECHNOLOGY NEW PLANT 2018 Start of the project 2020 Adaptation to vaccine 2021 AEMPS authorization 40M€ +100 +30M VIALS manufacturing PRODUCTIVE PLANT 15
Slide 21: New injectable and lyophilizate plant timeline
NEW RJ INJECTABLE & LYOPHILIZATE PLANT ● BARCELONA 2018 2020 2021 Inicio del Adaptación Autorización proyecto fabricación AEMPS vacunas 2121
Slide 22: R&D: opportunities and key challenges for the future
R&D | OVERALL OPPORTUNITIES AND KEY CHALLENGES FOR THE FUTURE ESSENTIAL OTHER MEDICINAL MEDICINAL PRODUCTS PRODUCTS CHEMICAL BASE COMBATING INNOVATIVE MULTI-RESISTANCE AND ANTIBIOTICS OFF-PATENT VACCINES MEDICINAL NEW PRODUCTS TREATMENTS BIOLOGICAL BASE HUMAN INNOVATIVE ADVANCED THERAPIES AND AND mR
Slide 23: RJF Share Performance
RJF SHARE PERFORMANCE 03 Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail
Slide 24: RJF Share Performance 2022
RJF SHARE PERFORMANCE 2022 MARKET CAPITALISATION €172 million Data as at 31 December 2022 SCRIP DIVIDEND 2022 4,00 • Remuneration €0.04/right cash or shares Close • 97.2% of shareholders opt for shares 3,50 31/12/21 • 990,533 shares issued (1.26% capital) 3,00 €3.26 2,50 AVERAGE DAILY VOLUME 2,00 •
Slide 25: Links and Supplementary Information
LINKS AND SUPPLEMENTARY INFORMATION LATEST NEWS RESULTS WEBCAST SUBSCRIPTION CENTRE https://reigjofre.com/en/news/ https://reigjofre.com/en/investors/webcasts/ https://reigjofre.com/en/news/subscription-center/
Slide 26: Thank you
Thank you Av. de les Flors 08970 Sant Joan Despí Barcelona, Spain T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com